Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%

Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.